二甲双胍与2型糖尿病患者哮喘的发展
2022/07/19
摘要
我们进行这项研究是为了比较二甲双胍使用者和非使用者之间哮喘发展和加重的风险。总的来说，在2000年1月1日至2017年12月31日期间，从台湾国家健康保险研究数据库中确定了57743个倾向评分匹配的二甲双胍使用者和非使用者。我们使用具有稳健标准误差估计的Cox比例风险模型来比较2型糖尿病（T2D）参与者哮喘发作、加重和住院的风险。与不使用二甲双胍相比，二甲双胍在哮喘发展、加重和住院治疗中的AHR（95%CI）分别为1.13（1.06-1.2）、1.62（1.35-1.95）和1.5（1.22-1.85）。二甲双胍使用者的哮喘发展、加重和住院的累积发病率显著高于非使用者（p&;lt；0.001）。与不使用二甲双胍相比，累积使用二甲双胍超过728天的时间与显著更高的预后风险相关。我们的研究表明，二甲双胍使用者的哮喘发展、加重和住院风险显著高于非二甲双胍使用者。此外，二甲双胍使用超过728天与更高的预后风险相关。一项随机对照研究证实了我们的结果。
Metformin and the Development of Asthma in Patients with Type 2 Diabetes.
Fu-Shun Yen, Chih-Cheng Hsu, Ying-Hsiu Shih, Wei-Lin Pan, James Cheng-Chung Wei, Chii-Min Hwu
Abstract
We conducted this study to compare the risks of asthma development and exacerbation between metformin users and nonusers. Overall, 57,743 propensity score-matched metformin users and nonusers were identified from Taiwan's National Health Insurance Research Database between 1 January 2000, and 31 December 2017. We used the Cox proportional hazards model with robust standard error estimates to compare the risks of asthma onset, exacerbation, and hospitalization for asthma in participants with type 2 diabetes (T2D). Compared with metformin nonuse, the aHRs (95% CI) for metformin use in asthma development, exacerbation, and hospitalization for asthma were 1.13 (1.06-1.2), 1.62 (1.35-1.95), and 1.5 (1.22-1.85), respectively. The cumulative incidences of asthma development, exacerbation, and hospitalization for asthma were significantly higher in metformin users than nonusers (p < 0.001). A longer cumulative duration of metformin use for more than 728 days was associated with significantly higher risks of outcomes than metformin nonuse. Our study demonstrated that metformin users showed significantly higher risks of asthma development, exacerbation, and hospitalization for asthma than metformin nonusers. Moreover, metformin use for more than 728 days was associated with higher risks of outcomes. A randomized control study is warranted to verify our results.
我们进行这项研究是为了比较二甲双胍使用者和非使用者之间哮喘发展和加重的风险。总的来说，在2000年1月1日至2017年12月31日期间，从台湾国家健康保险研究数据库中确定了57743个倾向评分匹配的二甲双胍使用者和非使用者。我们使用具有稳健标准误差估计的Cox比例风险模型来比较2型糖尿病（T2D）参与者哮喘发作、加重和住院的风险。与不使用二甲双胍相比，二甲双胍在哮喘发展、加重和住院治疗中的AHR（95%CI）分别为1.13（1.06-1.2）、1.62（1.35-1.95）和1.5（1.22-1.85）。二甲双胍使用者的哮喘发展、加重和住院的累积发病率显著高于非使用者（p&;lt；0.001）。与不使用二甲双胍相比，累积使用二甲双胍超过728天的时间与显著更高的预后风险相关。我们的研究表明，二甲双胍使用者的哮喘发展、加重和住院风险显著高于非二甲双胍使用者。此外，二甲双胍使用超过728天与更高的预后风险相关。一项随机对照研究证实了我们的结果。
(中日友好医院呼吸与危重症医学科 顾宪民 摘译 林江涛 审校)
(Int J Environ Res Public Health. 2022 Jul 5;19(13):8211. doi: 10.3390/ijerph19138211.)
(Int J Environ Res Public Health. 2022 Jul 5;19(13):8211. doi: 10.3390/ijerph19138211.)
Metformin and the Development of Asthma in Patients with Type 2 Diabetes.
Fu-Shun Yen, Chih-Cheng Hsu, Ying-Hsiu Shih, Wei-Lin Pan, James Cheng-Chung Wei, Chii-Min Hwu
Abstract
We conducted this study to compare the risks of asthma development and exacerbation between metformin users and nonusers. Overall, 57,743 propensity score-matched metformin users and nonusers were identified from Taiwan's National Health Insurance Research Database between 1 January 2000, and 31 December 2017. We used the Cox proportional hazards model with robust standard error estimates to compare the risks of asthma onset, exacerbation, and hospitalization for asthma in participants with type 2 diabetes (T2D). Compared with metformin nonuse, the aHRs (95% CI) for metformin use in asthma development, exacerbation, and hospitalization for asthma were 1.13 (1.06-1.2), 1.62 (1.35-1.95), and 1.5 (1.22-1.85), respectively. The cumulative incidences of asthma development, exacerbation, and hospitalization for asthma were significantly higher in metformin users than nonusers (p < 0.001). A longer cumulative duration of metformin use for more than 728 days was associated with significantly higher risks of outcomes than metformin nonuse. Our study demonstrated that metformin users showed significantly higher risks of asthma development, exacerbation, and hospitalization for asthma than metformin nonusers. Moreover, metformin use for more than 728 days was associated with higher risks of outcomes. A randomized control study is warranted to verify our results.
上一篇：
气道自身抗体是哮喘严重程度的决定因素
下一篇：
无症状健康哮喘儿童的肺部超声表现
